Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate the ease of use of the U300 pen injector in pen-naïve and insulin-naïve type 2
diabetes mellitus (T2DM) patients in a 4-week once-daily dosing regimen with HOE901-U300.
Secondary Objectives:
To assess in a 4-week once-daily dosing regimen with HOE901-U300 in pen-naïve and
insulin-naïve T2DM patients.
The safety and usability of the U300 pen injector. The glycemic control with the U300 pen
injector. The safety of HOE901-U300.